Cargando…

Evaluation of a New Survivin ELISA and UBC(®) Rapid for the Detection of Bladder Cancer in Urine

Urine-based biomarkers for non-invasive diagnosis of bladder cancer are urgently needed. No single marker with sufficient sensitivity and specificity has been described so far. Thus, a combination of markers appears to be a promising approach. The aim of this case-control study was to evaluate the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Gleichenhagen, Jan, Arndt, Christian, Casjens, Swaantje, Meinig, Carmen, Gerullis, Holger, Raiko, Irina, Brüning, Thomas, Ecke, Thorsten, Johnen, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796175/
https://www.ncbi.nlm.nih.gov/pubmed/29324722
http://dx.doi.org/10.3390/ijms19010226
_version_ 1783297450605281280
author Gleichenhagen, Jan
Arndt, Christian
Casjens, Swaantje
Meinig, Carmen
Gerullis, Holger
Raiko, Irina
Brüning, Thomas
Ecke, Thorsten
Johnen, Georg
author_facet Gleichenhagen, Jan
Arndt, Christian
Casjens, Swaantje
Meinig, Carmen
Gerullis, Holger
Raiko, Irina
Brüning, Thomas
Ecke, Thorsten
Johnen, Georg
author_sort Gleichenhagen, Jan
collection PubMed
description Urine-based biomarkers for non-invasive diagnosis of bladder cancer are urgently needed. No single marker with sufficient sensitivity and specificity has been described so far. Thus, a combination of markers appears to be a promising approach. The aim of this case-control study was to evaluate the performance of an in-house developed enzyme-linked immunosorbent assay (ELISA) for survivin, the UBC(®) Rapid test, and the combination of both assays. A total of 290 patients were recruited. Due to prior bladder cancer, 46 patients were excluded. Urine samples were available from 111 patients with bladder cancer and 133 clinical controls without urologic diseases. Antibodies generated from recombinant survivin were utilized to develop a sandwich ELISA. The ELISA and the UBC(®) Rapid test were applied to all urine samples. Receiver operating characteristic (ROC) analysis was used to evaluate marker performance. The survivin ELISA exhibited a sensitivity of 35% with a specificity of 98%. The UBC(®) Rapid test showed a sensitivity of 56% and a specificity of 96%. Combination of both assays increased the sensitivity to 66% with a specificity of 95%. For high-grade tumors, the combination showed a sensitivity of 82% and a specificity of 95%. The new survivin ELISA and the UBC(®) Rapid test are both able to detect bladder cancer, especially high-grade tumors. However, the performance of each individual marker is moderate and efforts to improve the survivin assay should be pursued. A combination of both assays confirmed the benefit of using marker panels. The results need further testing in a prospective study and with a high-risk population.
format Online
Article
Text
id pubmed-5796175
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-57961752018-02-09 Evaluation of a New Survivin ELISA and UBC(®) Rapid for the Detection of Bladder Cancer in Urine Gleichenhagen, Jan Arndt, Christian Casjens, Swaantje Meinig, Carmen Gerullis, Holger Raiko, Irina Brüning, Thomas Ecke, Thorsten Johnen, Georg Int J Mol Sci Article Urine-based biomarkers for non-invasive diagnosis of bladder cancer are urgently needed. No single marker with sufficient sensitivity and specificity has been described so far. Thus, a combination of markers appears to be a promising approach. The aim of this case-control study was to evaluate the performance of an in-house developed enzyme-linked immunosorbent assay (ELISA) for survivin, the UBC(®) Rapid test, and the combination of both assays. A total of 290 patients were recruited. Due to prior bladder cancer, 46 patients were excluded. Urine samples were available from 111 patients with bladder cancer and 133 clinical controls without urologic diseases. Antibodies generated from recombinant survivin were utilized to develop a sandwich ELISA. The ELISA and the UBC(®) Rapid test were applied to all urine samples. Receiver operating characteristic (ROC) analysis was used to evaluate marker performance. The survivin ELISA exhibited a sensitivity of 35% with a specificity of 98%. The UBC(®) Rapid test showed a sensitivity of 56% and a specificity of 96%. Combination of both assays increased the sensitivity to 66% with a specificity of 95%. For high-grade tumors, the combination showed a sensitivity of 82% and a specificity of 95%. The new survivin ELISA and the UBC(®) Rapid test are both able to detect bladder cancer, especially high-grade tumors. However, the performance of each individual marker is moderate and efforts to improve the survivin assay should be pursued. A combination of both assays confirmed the benefit of using marker panels. The results need further testing in a prospective study and with a high-risk population. MDPI 2018-01-11 /pmc/articles/PMC5796175/ /pubmed/29324722 http://dx.doi.org/10.3390/ijms19010226 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gleichenhagen, Jan
Arndt, Christian
Casjens, Swaantje
Meinig, Carmen
Gerullis, Holger
Raiko, Irina
Brüning, Thomas
Ecke, Thorsten
Johnen, Georg
Evaluation of a New Survivin ELISA and UBC(®) Rapid for the Detection of Bladder Cancer in Urine
title Evaluation of a New Survivin ELISA and UBC(®) Rapid for the Detection of Bladder Cancer in Urine
title_full Evaluation of a New Survivin ELISA and UBC(®) Rapid for the Detection of Bladder Cancer in Urine
title_fullStr Evaluation of a New Survivin ELISA and UBC(®) Rapid for the Detection of Bladder Cancer in Urine
title_full_unstemmed Evaluation of a New Survivin ELISA and UBC(®) Rapid for the Detection of Bladder Cancer in Urine
title_short Evaluation of a New Survivin ELISA and UBC(®) Rapid for the Detection of Bladder Cancer in Urine
title_sort evaluation of a new survivin elisa and ubc(®) rapid for the detection of bladder cancer in urine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796175/
https://www.ncbi.nlm.nih.gov/pubmed/29324722
http://dx.doi.org/10.3390/ijms19010226
work_keys_str_mv AT gleichenhagenjan evaluationofanewsurvivinelisaandubcrapidforthedetectionofbladdercancerinurine
AT arndtchristian evaluationofanewsurvivinelisaandubcrapidforthedetectionofbladdercancerinurine
AT casjensswaantje evaluationofanewsurvivinelisaandubcrapidforthedetectionofbladdercancerinurine
AT meinigcarmen evaluationofanewsurvivinelisaandubcrapidforthedetectionofbladdercancerinurine
AT gerullisholger evaluationofanewsurvivinelisaandubcrapidforthedetectionofbladdercancerinurine
AT raikoirina evaluationofanewsurvivinelisaandubcrapidforthedetectionofbladdercancerinurine
AT bruningthomas evaluationofanewsurvivinelisaandubcrapidforthedetectionofbladdercancerinurine
AT eckethorsten evaluationofanewsurvivinelisaandubcrapidforthedetectionofbladdercancerinurine
AT johnengeorg evaluationofanewsurvivinelisaandubcrapidforthedetectionofbladdercancerinurine